68Ga标记生长抑素受体配体PET/CT对不稳定颈动脉斑块的显像
研究前瞻性纳入20例近期有症状性颈动脉事件、拟行颈动脉内膜剥脱术的患者,术前行颈部68Ga-DOTATATE PET/CT,并在切除斑块中行sst2免疫组化。结果显示症状性斑块与对侧颈动脉/斑块的SUV及靶本比无显著差异(n=19,P>0.10),所有切除斑块均未见细胞膜表达sst2的细胞,作者认为sst2 PET/CT在检测和表征症状性颈动脉斑块中不太可能发挥作用。
要点
- 症状性斑块与对侧颈动脉/斑块的68Ga-DOTATATE摄取无显著差异(n=19,P>0.10)。
- SUV的组内相关系数均大于0.8,靶本比几乎均大于0.6。
- 切除斑块均未见细胞膜表达sst2的细胞,PET活性非sst2受体介导。
核心结论
- 近期症状性颈动脉斑块的68Ga-DOTATATE PET活性与对侧颈动脉/斑块无显著差异。
- PET所见活性未显示来自体外特异性sst2受体介导的摄取。
- 作者认为sst2 PET/CT显像不太可能在症状性颈动脉斑块的检测和表征中发挥作用。
研究设计与样本
- 前瞻性研究,连续纳入20例近期有症状性颈动脉事件(短暂性脑缺血发作、卒中或一过性黑矇)、拟行颈动脉内膜剥脱术并同意参加的患者。
- 术前行颈部68Ga-DOTATATE PET/CT,由一名有经验的核医学放射科医师和放射技师沿颈动脉斑块及对侧斑块/颈动脉勾画感兴趣区测量摄取。
- 评估两种PET定量方法及观察者间和观察者内变异性,取切除颈动脉斑块行生长抑素受体亚型2(sst2)免疫组化染色。
主要发现
- 研究PET与手术之间的中位时间间隔为2 d。
- 症状性斑块与无症状对侧颈动脉/斑块的SUV和靶本比无论采用何种定量方法均无显著差异(n=19,P>0.10)。
- 颈动脉/斑块摄取(SUV)各项测量的组内相关系数均大于0.8,靶本比几乎各项测量的组内相关系数均大于0.6。
- 所有切除斑块均未见细胞(巨噬细胞、淋巴细胞、血管相关细胞)在细胞膜上表达sst2。
临床怎么用
- 作者认为sst2 PET/CT显像不太可能在症状性颈动脉斑块的检测和表征中发挥作用。
局限性
- 作者结论认为sst2 PET/CT显像不太可能在症状性颈动脉斑块的检测和表征中发挥作用,原文未另述研究局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
68Ga-labeled somatostatin receptor ligand PET imaging has recently been shown in preclinical and early human studies to have a potential role in the evaluation of vulnerable arterial plaques. We prospectively evaluated carotid plaque 68Ga-DOTATATE uptake in patients with recent carotid events, assessed inter- and intraobserver variability of such measurements, and explored the mechanism of any plaque DOTATATE activity with immunohistochemistry in resected specimens. Methods: Twenty consecutively consenting patients with recent symptomatic carotid events (transient ischemic attack, stroke, or amaurosis fugax), due for carotid endarterectomy, were prospectively recruited. 68Ga-DOTATATE PET/CT of the neck was performed before surgery. 68Ga-DOTATATE uptake was measured by drawing regions of interest along the carotid plaques and contralateral plaques/carotid arteries by an experienced radionuclide radiologist and radiographer. Two PET quantification methods with inter- and intraobserver variability were assessed. Resected carotid plaques were retrieved for somatostatin receptor subtype-2 (sst2) immunohistochemical staining. Results: The median time delay between research PET and surgery was 2 d. SUVs and target-to-background ratios for the symptomatic plaques and the asymptomatic contralateral carotid arteries/plaques showed no significant difference (n = 19, P > 0.10), regardless of quantification method. The intraclass correlation coefficient was greater than 0.8 in all measures of carotid artery/plaque uptake (SUV) and greater than 0.6 in almost all measures of target-to-background ratio. None of the excised plaques was shown to contain cells (macrophages, lymphocytes, vessel-associated cells) expressing sst2 on their cell membrane. Conclusion:68Ga-DOTATATE activity on PET in recently symptomatic carotid plaques is not significantly different from contralateral carotids/plaques. Any activity seen on PET is not shown to be from specific sst2 receptor-mediated uptake in vitro. It is therefore unlikely that sst2 PET/CT imaging will have a role in the detection and characterization of symptomatic carotid plaques.
引用
- Wan MYS, Endozo R, Michopoulou S, et al. PET/CT Imaging of Unstable Carotid Plaque with 68Ga-Labeled Somatostatin Receptor Ligand. J Nucl Med. 2016. PMID: 27932558. doi:10.2967/jnumed.116.181438
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。